隶属于 赛诺菲安万特
相关临床试验
13
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
进行中（未招募）
6
46.1%
已完成
1
7.7%
招募中
5
38.5%
终止
1
7.7%
暂无批准数据
- Inhibrx reported a $36.7 million net loss for Q2 2026, up from $28.7 million a year earlier, driven by BLA-preparation manufacturing costs and pre-launch spending. - The FDA accepted the biologics license application for ozekibart in conventional chondrosarcoma and set a PDUFA goal date of April 14, 2027. - Inhibrx plans to announce progression-free survival data from the randomized Phase 2 trial of INBRX-106 in head and neck squamous cell carcinoma in Q3 2026. - The company secured an additional $325 million in potential financing from Oxford Finance and held $219.5 million in cash as of August 6, 2026.
- Inhibrx Biosciences reported positive updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) combined with FOLFIRI in patients with locally advanced or metastatic colorectal cancer. - The company announced plans to submit a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma by April 2026. - Transcenta holds exclusive rights to develop and commercialize ozekibart in Greater China through its subsidiary HJB and is actively evaluating regional development plans. - The positive developments represent significant progress for ozekibart across multiple oncology indications with potential regulatory milestones on the horizon.
- Sanofi's efdoralprin alfa demonstrated superior efficacy in raising alpha-1 antitrypsin protein levels compared to standard plasma-derived therapy in a 97-patient head-to-head trial. - The experimental therapy, administered every three weeks, achieved 24.1 micromolar trough levels at week 32 versus 7.6 micromolar for weekly standard treatment. - Patients maintained normal AAT levels throughout the study on Sanofi's therapy, compared to less than half the time for those on standard care. - The recombinant technology-based drug could reduce dependence on donated plasma and offer more convenient dosing for the estimated 235,000 patients with this genetic lung disease.
- INBRX-106 combined with pembrolizumab achieved a 44.0% confirmed objective response rate versus 21.4% with pembrolizumab alone in first-line head and neck squamous cell carcinoma patients. - The combination demonstrated superior depth of response with three complete radiographic responses and up to 15-fold increase in systemic T-cell expansion compared to pembrolizumab monotherapy. - The hexavalent OX40 agonist showed a manageable safety profile with predominantly low-grade adverse events and no treatment-related deaths reported. - Inhibrx plans to initiate Phase 3 studies in Q3 2026 and expand into non-small cell lung cancer trials based on these promising results.
- Inhibrx Biosciences has attracted interest from Merck & Co, Merck KGaA, and Ono Pharmaceutical for its experimental cancer drug INBRX-106, potentially valued at over $8 billion. - INBRX-106 is designed to boost Keytruda's efficacy, with preliminary Phase 2/3 trial data showing improved response rates from 30% to 45% when combined with the immunotherapy. - The biotech is exploring a joint spin-off of INBRX-106 and ozekibart, with combined potential value exceeding $9 billion if clinical trials succeed. - Multiple top-tier pharmaceutical companies including Eli Lilly, AstraZeneca, Pfizer, and J&J are reportedly interested in the immuno-oncology asset.
- Inhibrx Biosciences will host a webcast on April 21, 2026, to provide clinical updates on ozekibart (INBRX-109) in combination with FOLFIRI for late-line colorectal cancer patients. - Ozekibart is a precision-engineered tetravalent death receptor 5 (DR5) agonist antibody that has already demonstrated breakthrough efficacy in chondrosarcoma trials. - The company's ChonDRAgon study showed ozekibart achieved a 52% reduction in disease progression risk and more than doubled median progression-free survival compared to placebo. - This represents the first investigational therapy to demonstrate significant progression-free survival benefit in a randomized chondrosarcoma trial, addressing an unmet medical need in a disease with no approved systemic options.
- Inhibrx has recruited 46 of 60 patients in its Phase 2/3 trial evaluating INBRX-106 plus Keytruda versus Keytruda alone for first-line treatment of head and neck squamous cell carcinoma, with enrollment completion expected in Q1 2026. - The company completed enrollment of 34 patients in November 2025 for its Phase 1/2 trial of INBRX-106 plus Keytruda in checkpoint inhibitor refractory or relapsed non-small cell lung cancer. - Ozekibart expansion cohorts show progress with 44 patients enrolled in colorectal cancer combination therapy, demonstrating well-tolerated treatment with durable responses and high disease control rates. - Data maturity for both INBRX-106 programs is expected in the second half of 2026, while ozekibart progression-free survival data should mature in Q2 2026.
- Inhibrx Biosciences reported positive topline results from its pivotal Phase 2 ChonDRAgon trial evaluating ozekibart in advanced chondrosarcoma, showing meaningful improvement in patient outcomes. - The breakthrough results triggered a 102% single-day share price gain, pushing the company's year-to-date return to 276% and highlighting strong investor optimism. - Despite the rally, the company's current price-to-book ratio of 12.1x significantly exceeds industry averages, raising questions about valuation sustainability. - The stock's premium valuation reflects high market expectations for ozekibart's future commercial potential, though clinical setbacks could challenge current optimism.
- Inhibrx Biosciences will host a webcast on October 23, 2025, to present topline results from the registrational ChonDRAgon study of ozekibart in advanced chondrosarcoma patients. - The Phase 2 trial evaluates ozekibart as a single agent versus placebo in patients with metastatic or unresectable conventional chondrosarcoma. - The company will also provide updates on expansion trials investigating ozekibart combinations in colorectal cancer and Ewing sarcoma. - Ozekibart is a precision-engineered DR5 agonist antibody with FDA Fast Track and orphan drug designations for chondrosarcoma treatment.
- Inhibrx Biosciences announced preliminary Phase 1 data for ozekibart (INBRX-109) combined with FOLFIRI in advanced colorectal adenocarcinoma, presented at ASCO GI Cancers Symposium. - The trial showed one complete response, three partial responses, and six cases of stable disease in 10 evaluable patients, with 46.2% achieving durable disease control. - Ozekibart-related adverse events were mostly low-grade, with the most common being nausea, increased alanine aminotransferase, diarrhea, and fatigue. - An expansion cohort enrolling up to 50 patients with 2-3 prior lines of therapy has been initiated to validate these findings, with data expected in Q3 2025.
